new_0222_0234|KROS|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0234|KROS|1|Keros Therapeutics Inc Total Current Assets (Quarterly) (USD)|Keros Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Keros Therapeutics Inc Inventories (Quarterly) (USD)|Keros Therapeutics Inc Net PP&E (Quarterly) (USD)|Keros Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Keros Therapeutics Inc Total Liabilities (Quarterly) (USD)|Keros Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Keros Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Keros Therapeutics Inc Total Deposits (Quarterly) (USD)|Keros Therapeutics Inc Book Value (Quarterly) (USD)|Keros Therapeutics Inc Retained Earnings (Quarterly) (USD)|Keros Therapeutics Inc Treasury Stock (Quarterly) (USD)|Keros Therapeutics Inc EV to Revenues|Keros Therapeutics Inc EV to Earnings|Keros Therapeutics Inc EV to Free Cash Flow|Keros Therapeutics Inc EV to Assets (Quarterly)|Keros Therapeutics Inc PS Ratio|Keros Therapeutics Inc PE Ratio|Keros Therapeutics Inc Price to Book Value|Keros Therapeutics Inc PEG Ratio|Keros Therapeutics Inc Debt to Equity Ratio|Keros Therapeutics Inc Dividend Yield|Keros Therapeutics Inc Shareholder Yield (TTM)|Keros Therapeutics Inc Percent of Shares Outstanding Short|Keros Therapeutics Inc Total Receivables (Quarterly) (USD)|Keros Therapeutics Inc Total Payables (Quarterly) (USD)|Keros Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Keros Therapeutics Inc Return on Invested Capital|Keros Therapeutics Inc Quality Ratio Score|Keros Therapeutics Inc Momentum Score|Keros Therapeutics Inc Beta (1Y)|Keros Therapeutics Inc Sustainable Growth Rate (TTM)|Keros Therapeutics Inc Institutional Investor Ownership Percentage|Keros Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Keros Therapeutics Inc Total Employees (Annual)|Keros Therapeutics Inc EPS Diluted (Quarterly) (USD)|Keros Therapeutics Inc SG&A Expense (Quarterly) (USD)|Keros Therapeutics Inc Shares Outstanding|Keros Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Keros Therapeutics Inc Ordinary Shares Number (Quarterly)|Keros Therapeutics Inc Payout Ratio|Keros Therapeutics Inc Quick Ratio (Quarterly)|Keros Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Keros Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Keros Therapeutics Inc Effective Tax Rate (TTM)|Keros Therapeutics Inc Return on Equity|Keros Therapeutics Inc Net Income (TTM) (USD)|Keros Therapeutics Inc Revenue (TTM) (USD)|Keros Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Keros Therapeutics Inc Revenue (Quarterly) (USD)|Keros Therapeutics Inc Gross Profit (Quarterly) (USD)|Keros Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Keros Therapeutics Inc Net Income (Quarterly) (USD)|Keros Therapeutics Inc Net Interest Income (Quarterly) (USD)|Keros Therapeutics Inc Price (USD)|Keros Therapeutics Inc Total Return Price (USD)|Keros Therapeutics Inc Enterprise Value (USD)|Keros Therapeutics Inc 30-Day Average Daily Volume|Keros Therapeutics Inc 1 Year Price Returns (Daily)|Keros Therapeutics Inc Short Interest|Keros Therapeutics Inc PE Ratio (Forward)|Keros Therapeutics Inc PE Ratio (Forward 1y)|Keros Therapeutics Inc PS Ratio (Forward)|Keros Therapeutics Inc PS Ratio (Forward 1y)|Keros Therapeutics Inc Quarterly EPS Estimates (USD)|Keros Therapeutics Inc Quarterly Revenue Estimates (USD)|Keros Therapeutics Inc Quarterly EPS Surprise|Keros Therapeutics Inc Quarterly Revenue Surprise|Keros Therapeutics Inc Quarterly Actual EPS (USD)|Keros Therapeutics Inc Quarterly Actual Revenue (USD)|Keros Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Keros Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Keros Therapeutics Inc Price Target (USD)|Keros Therapeutics Inc Consensus Recommendation|Keros Therapeutics Inc Price Target Num Estimates|Keros Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Keros Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Keros Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Keros Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Keros Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Keros Therapeutics Inc Land and Improvements (Quarterly) (USD)|Keros Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Keros Therapeutics Inc Other Properties (Quarterly) (USD)|Keros Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0234|KROS|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0234|KROS|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|daily|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0234|KROS|5|91.2857142857|91.2857142857||91.2857142857||91.2857142857|91.2857142857|91.2857142857||91.2857142857|91.2857142857|||91.4|1.44585987261|91.4|||1.44444444444|1.44755244755|91.1666666667|1.44585987261|91.25|15.2558139535|91.2857142857|91.2857142857|91.2857142857|91.25||30.7142857143|30.6666666667|91.25||91.4|91.2857142857|91.4|91.4|33.8235294118||91.2857142857|91.1666666667|91.1666666667|91.4|91.4444444444|91.2857142857|91.25|91.2857142857|||91.3333333333||91.4|91.4|91.4|1.44585987261|1.44585987261|1.44585987261|1.44570135747|1.43636363636|15.2558139535|||1.45019920319||91.3636363636|91.3636363636|91.3333333333|91.5|91.3333333333|91.3333333333|40.875|54.5|36.4375|18.1666666667|36.4375|27.25|29.7272727273|91.4|91.4|91.375|||91.2857142857|91.5||
new_0222_0234|KROS|6|7|7||7||7|7|7||7|7|||5|471|5|||414|286|6|471|4|43|7|7|7|4||7|9|4||10|7|10|10|17||7|6|6|10|9|7|4|7|||9||10|10|10|471|471|471|442|220|43|||251||11|11|6|2|6|6|16|12|16|36|16|24|22|10|10|8|||7|4||
new_0222_0234|KROS|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0234|KROS|201903||||||||||||||||||||||||||||||||||8.8822||-0.409|0.491||||||-0.3584|||||||2.5||-3.183|-3.183|-0.002||||||||||||||||||||||||4.867|0.045|||||||
new_0222_0234|KROS|201906||||||||||||||||||||||||||||||||||8.8822||-0.3719|0.654||||||-0.3212|||||||2.5||-2.853|-2.853|-0.002||||||||||||||||||||||||4.497|0.049|||||||
new_0222_0234|KROS|201909||||||||||||||||||||||||||||||||||8.8822||-0.4502|0.972||||||-0.3996|||||||2.5||-3.549|-3.549|-0.003||||||||||||||||||||||||3.854|0.055|0.003||||||
new_0222_0234|KROS|201912|8.927|7.02||1.913||10.46|4.486|5.974||-19.446|-19.65||||||||||||||0.922|2.131|19.942|||||||18.1894|23|-0.176|1.067|||18.1894||1.7704|-0.1512||||-12.336|10||2.5||-2.751|-2.751|-0.001||||||||||||||||||||||||4.161|0.059|0.001|||2.048|0.077||
new_0222_0234|KROS|202003|58.539|54.518||1.938||9.737|8.836|0.901||-24.867|-31.542||||-27.8816|||||||||1.5651|1.073|2.469|75.723|||||||18.1894|26|-0.6981|1.977|20.0894||18.1894||6.2914|-0.6538||0.8107||-21.045|||||-12.064|-11.892|-0.002|29.55|29.55|614.8458|57253.7||314420|||||-0.8025|0.0625|-536.7601|-100|-5.11||0.1875|0.25|43.5|1.5|4|-4.2325|-3.28|8.527|0.063|0.002|||1.938||28.74|
new_0222_0234|KROS|202006|148.517|144.687||1.806||9.077|8.294|0.783||141.361|-42.299|||-21.1214|-22.8116|4.0644|||5.3489||||-13.5786|6.4616|0.238|4.852|0.002|-45.0659||||-89.4887||17.624|28|-0.62|3.65|20.1581||20.1581||17.4735|-0.62|-102.672|0.5906|-89.4887|-28.949|||||-10.757|-10.757|-0.001|37.51|37.51|611.4433|126269.9||1302544|||||-0.675|0.0625|8.1481|-100|-0.62||0.1875|0.25|43.5|1.5|4|-4.2475|-3.1925|7.264|0.068|0.001|||1.806||32.1|53.54
new_0222_0234|KROS|202009|136.416|133.81||1.715||7.488|6.825|0.663||130.758|-54.335|||-17.2228|-18.606|4.6638|||5.9542||||-13.1874|1.5778|0.172|1.716|0.002|-46.2932||||-65.7331||20.1759|32|-0.6|3.553|20.1857||20.1857||19.6311|-0.6||0.4573|-65.7331|-37.436|||||-12.036|-12.036|-0.002|38.57|38.57|644.7524|81236.6||318481|||||-0.595|0.0625|-0.8403|-100|-0.6||||47.25|1.5|4|-4.5133|-2.5925|8.395|0.072|0.002|||1.715||55.6|75.61
new_0222_0234|KROS|202012|267.726|265.876||1.602||7.722|7.184|0.538||261.721|-65.011|||-30.2055|-36.8439|5.0851|||6.251|-0.4118|||-14.8654|3.9544|0.216|2.334|0.002|-38.7575||||-46.3315||21.6678|35|-0.49|3.617|23.1929||23.1929||37.0395|-0.49|-140.53|0.3777|-46.3315|-45.361|||||-10.676|-10.676|-0.001|70.54|70.54|1370.1512|227214.8333||917144|||16360.2717||-0.57||14.0351||-0.49||||86.25|1.5|4|-4.145|-2.545|9.674|0.075|0.001|||1.984|0.082|57.05|65.47
new_0222_0234|KROS|202103|255.982|255.203||1.633||9.358|8.95|0.408||248.372|-80.896|||-23.8513|-29.721|4.5674|||5.767|-0.6296|||-16.9791|4.4507||3.148|0.002|-29.6219|||2.3268|-32.5836||23.2298|38|-0.68|4.274|23.2715||23.2715||28.5143|-0.68||-0.1014|-32.5836|-49.354|||||-15.835|-15.885|-0.001|61.55|61.55|1177.1578|113693.5333|98.9848|1035743|||14323.6082||-0.58||-17.2414||-0.68||||86.25|1.5|4|-2.6125|-3.69|11.495|0.08|0.001|||1.633||58.8|54.56
new_0222_0234|KROS|202106|241.417|237.113||1.929||7.805|7.531|0.274||235.656|-96.518|||-13.9003|-15.7673|3.0956|||4.2043|-0.6827|||-14.1839|3.7464|0.245|1.478|0.002|-26.6336||7|2.8057|-26.6336||23.3057|44|-0.67|5.658|23.3288||23.3288||31.5175|-0.67||-0.0923|-26.6336|-54.219|||0.1||-15.622|-15.622|-0.001|42.47|42.47|753.6611|142014.9667|13.2231|873997|||9907.7414||-0.655||-2.2901||-0.67|0.1|0.1||87.5|1.5|4|-2.845|-3.8425|9.983|0.091|0.001|||1.929||36.8|33.64
new_0222_0234|KROS|202109|226.074|221.349||2.56||11.484|11.015|0.469||218.478|-116.815|||-12.9886|-13.6746|2.8926|||4.2365|-0.6359||||4.4157|0.169|2.894|0.002|||2|0.0415|||23.3622|45|-0.87|5.365|23.3968||23.3968|||-0.87||-0.0192||-62.48|||||-20.335|-20.297|-0.001|39.56|39.56|704.2284|238612.6667|2.5668|1033125|||9255.7741||-0.7225||-20.4152||-0.87||||86.25|1.5|4|-2.89|-4.09|14.832|0.103|0.001|||2.56||41.72|55.79
new_0222_0234|KROS|202112|||||||||||||||-22.286||||6.2663|-0.9406||||3.4886||||||3|-1.2526||||||||||||||||||||||||58.51|58.51|1147.7089|182572.1|-17.0542|816276|||13173.4681||-0.9175||||||0.1||86.25|1.5|4|-3.1425|-4.155||||||||46.37|52.09
new_0222_0234|KROS|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.86|||||||||||||||||||||
new_0222_0234|KROS|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.92|||||||||||||||||||||
new_0222_0234|KROS|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.97|||||||||||||||||||||
new_0222_0234|KROS|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.99|||||||||||||||||||||